TITLE

Imatinib increased therapeutic window for thrombolysis in ischemic stroke

AUTHOR(S)
Jacob, Harry S.
PUB. DATE
October 2008
SOURCE
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p29
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses a study which suggests that imatinib can increase the time when patients suffering from a stroke can be treated with tissue plasminogen activator (TPA). The effect of TPA on a patient after three hours is stated. It also indicated the decrease in hemorrhage rate and the amount of hemoglobin associated with the ischemic hemisphere.
ACCESSION #
34781549

 

Related Articles

  • VTE prophylaxis with enoxaparin demonstrated to be superior to unfractionated heparin in acute stroke patients.  // Formulary;Mar2007, Vol. 42 Issue 3, p192 

    The article discusses the characteristics of enoxaparin as superior to unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients with partial paralysis. Prophylaxis in acute ischemic stroke patients with restricted mobility has been recommended by 4...

  • Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Sinclair, S.E.; Frighetto, L.; Loewen, P.S.; Sunderji, R.; Teal, P.; Fagan, S.C.; Marra, C.A. // PharmacoEconomics;Sep2001, Vol. 19 Issue 9, p927 

    Background: There are over 40000 ischaemic strokes annually in Canada, which result in significant morbidity, mortality and burden to the healthcare system. A recent, large clinical trial has evaluated tissue plasminogen activator (t-PA) intravenously for the treatment of acute...

  • Meeting continues focus on need for adjuncts to tPA use.  // Medical Technology & Devices Week;2/20/2007, Vol. 5 Issue 8, p2 

    This article focuses on the treatment for acute ischemic stroke patients in the U.S., which was discussed during the annual International Stroke Conference held in San Francisco, California. The event was sponsored by the American Stroke Association. Participants expressed concerns on the small...

  • Lack of Clinical Significance of Early Ischemic Changes on Computed Tomography in Acute Stroke. Patel, Suresh C.; Levine, Steven R.; Tilley, Barbara C.; Grotta, James C.; Lu, Mei; Frankel, Michael; Haley, E. Clarke; Brott, Thomas G.; Broderick, Joseph P.; Horowitz, Steven; Lyden, Patrick D.; Lewandowski, Christopher A.; Marler, John R.; Welch, K.M.A. // JAMA: Journal of the American Medical Association;12/12/2001, Vol. 286 Issue 22, p2830 

    Reports on a study to determine the frequency and significance of early ischemic changes (EIC) of baseline head computed tomography scans in the National Institute of Neurological Disorders and Stroke rt-PA (recombinant tissue plasminogen activator) Stroke Trial. Design and setting; Patients;...

  • Medics dealing with use of t-Pa in strokes. Scott, Lisa // Modern Healthcare;2/12/96, Vol. 26 Issue 7, p108 

    Reports on the risk involved in the use of tissue plasminogen activator (t-Pa) to prevent brain damage in some stroke victims. Importance of time in the administration of t-Pa; Caution from experts regarding the therapy; Risk of intracerebral hemorrhages or death; Handling of strokes as...

  • Imatinib for Acute Ischemic Stroke. Segal, Alan Z. // Neurology Alert;Sep2008, Vol. 27 Issue 1, p7 

    TISSUE PLASMINOGEN ACTIVATOR (tPA) REMAINS THE only FDA-approved medication for acute ischemic stroke and is limited in its scope to a very brief 3-hour time window. Attempts to use tPA beyond 3 hours have failed due to decreased efficacy and increased hemorrhage rates. Further studies suggest...

  • ISCHEMIC STROKE ORDERS--post tPA monitoring.  // ED Nursing;Oct2009 Supplement, p1 

    The article presents a questionnaire for ischemic stroke order-post tissue plasminogen activator (tPA) monitoring from Valley Baptist Health System in Brownsville, Texas.

  • Intravenous tPA Administration Inclusion/Exclusion Criteria For Ischemic Stroke.  // ED Nursing;Oct2009 Supplement, p1 

    The article presents the criteria for intravenous tissue plasminogen activator (tPA) administration inclusion/ exclusion for ischemic stroke.

  • EPITHET: Patients who suffer a stroke and have a perfusion-diffusion mismatch may benefit from tPA beyond the 3-hour window.  // Formulary;Apr2008, Vol. 43 Issue 4, p147 

    The article focuses on the efficacy of the tissue plasminogen activator (alteplase) (tPA) in treating patients who suffer from stroke and have perfusion-diffusion mismatch. According to the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET), the use of tPA on patients who had experienced...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics